Program
ARD-885
A development code. Also written as “ARD-885 Tablets”.
Its studies are mostly in Arthritis, Rheumatoid, led by Artivila (Shenzhen) Innovation Center.
Furthest: phase 1, since Nov 14, 20251 company-led study, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Artivila (Shenzhen) Innovation Center | 10 open or running | phase 1since Nov 14, 2025 | Nov 14, 2025 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 14, 2025First study: phase 1 study in Arthritis, RheumatoidFirst studyNCT07266207 · 94 enrolled · China
TargetBeta
“ARD-885 Tablet is a dual-target inhibitor of IRAK4 and IRAK1.”study text, by rule · the study
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07266207Arthritis, Rheumatoid · China | 1 | Completed | Aug 14, 2025 | 94 |
How it is read
Names in the registry
- “ARD-885 Tablets”, 1 entry
Codes read as this program: ARD885.
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.